Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Odin

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Parkinson'S Disease|October 19, 2023
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's DiseaseKristina Rosqvist, Per Odin
Parkinsonism & Related Disorders|February 4, 2010
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's diseaseAngelo Antonini, Per Odin
Journal of Medical Economics|October 29, 2014
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and GermanyEvelyn Walter, Per Odin
Progress in Brain Research|October 5, 2010
The challenge of non-motor symptoms in Parkinson's diseaseK Ray Chaudhuri, Per Odin
International Review of Neurobiology|April 10, 2022
Diagnostic work up: Laboratory and biomarkersGustav Cedergren Weber, Per Odin
International Review of Neurobiology|August 15, 2017
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor SymptomsUlrika Mundt-Petersen, Per Odin
Drug Safety|December 24, 2024
Drug-Induced Cognitive ImpairmentArne Reimers, Per Odin, Hanna Ljung
Journal of Neural Transmission (Vienna, Austria : 1996)|December 29, 2010
What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?Rüdiger Hilker, Angelo Antonini, Per Odin
Movement Disorders Clinical Practice|October 27, 2018
Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?Jonathan Timpka, Tove Henriksen, Per Odin
CNS Drugs|May 4, 2016
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic ReviewKarin Wirdefeldt, Per Odin, Dag Nyholm
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Parkinson'S Disease|October 19, 2023
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's DiseaseKristina Rosqvist, Per Odin
Parkinsonism & Related Disorders|February 4, 2010
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's diseaseAngelo Antonini, Per Odin
Journal of Medical Economics|October 29, 2014
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and GermanyEvelyn Walter, Per Odin
Progress in Brain Research|October 5, 2010
The challenge of non-motor symptoms in Parkinson's diseaseK Ray Chaudhuri, Per Odin
International Review of Neurobiology|April 10, 2022
Diagnostic work up: Laboratory and biomarkersGustav Cedergren Weber, Per Odin
International Review of Neurobiology|August 15, 2017
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor SymptomsUlrika Mundt-Petersen, Per Odin
Drug Safety|December 24, 2024
Drug-Induced Cognitive ImpairmentArne Reimers, Per Odin, Hanna Ljung
Journal of Neural Transmission (Vienna, Austria : 1996)|December 29, 2010
What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?Rüdiger Hilker, Angelo Antonini, Per Odin
Movement Disorders Clinical Practice|October 27, 2018
Non-oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?Jonathan Timpka, Tove Henriksen, Per Odin
CNS Drugs|May 4, 2016
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic ReviewKarin Wirdefeldt, Per Odin, Dag Nyholm
Pageof 17